News

This product will be manufactured at Lupin’s Pithampur facility in India

Norgestrel and Ethinyl Estradiol Tablets USP (RLD: Lo/Ovral-28) had estimated annual sales of $33 million in the U.S

The product will be manufactured at Lupin’s Goa facility in India

The company has achieved a key milestone for its novel MALT1

In terms of the BTA, the said transaction has been completed and transfer of API R&D Division is effective from July 01, 2025

In terms of the BTA, the said transaction has been completed, and transfer of OTC Business is effective from July 01, 2025

Diazepam Rectal Gel had estimated annual sales of $34 million in the U.S. (IQVIA MAT March 2023)

Lupin Diagnostics is committed to making preventive quality healthcare accessible and affordable to all

The inspection closed with the facility receiving an inspection classification of ‘No Action Indicated’

Through the signature of this collaboration with Lupin, Scope is expanding its footprint in Latin America

This product will be manufactured at Lupin’s Somerset facility in the US

Lupin is the exclusive first-to-file for this product and is eligible for 180 days of generic drug exclusivity

This product will be manufactured at Lupin’s Nagpur facility in India

Diazepam Rectal Gel (RLD Diastat AcuDial) had estimated annual sales of $37 million in the U.S.

With this acquisition, Lupin Healthcare (UK) gains full ownership of Renascience which, going forward, will trade as its subsidiary

The inspection was carried out from January 28, 2025 to February 1, 2025, and concluded with zero 483 observations

This product will be manufactured at Lupin’s Somerset facility in the US

A warning letter is issued when the US health regulator finds that a manufacturer has significantly violated its regulations

The company will have semi-exclusive rights to co-market the product in India under the brand name LINVAS

The inspection of the facility was conducted from August 16-19, 2022

Humrahi, translating to ‘Companion’ is a guide in the journey of diabetes management

Total consolidated income of the company decreased by 12.76% at Rs 3,749.40 crore for Q1FY23

Total consolidated income of the company increased by 29.00% at Rs 4,836.89 crore for Q1FY24

This product will be manufactured at Lupin’s Nagpur facility in India

Ipratropium Bromide Nasal Solution (RLD Atrovent) had estimated annual sales of $63 million in the U.S.

Drospirenone Tablets had estimated annual sales of $141 million in the U.S.

The product will be manufactured at Lupin’s facility in Nagpur, India

Rufinamide Tablets (RLD Banzel) had estimated annual sales of $138 million in the U.S.

The company has launched this important product under the brand name DIFIZMA in India

Dapagliflozin and Saxagliptin Tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

Darunavir Tablets, 600 mg and 800 mg had estimated annual sales of $308 million in the U.S.

With this acquisition, Lupin will gain access to Medisol’s portfolio of seven injectable products across four therapeutic areas

This product will be manufactured at Lupin’s Nagpur facility in India

The company is recalling the affected lot due to Current Good Manufacturing Practice deviations

The product will be manufactured at Lupin’s Pithampur facility in India

The product will be manufactured at Lupin’s facility in Goa, India

This collaboration marks a significant milestone in countering the disease burden by enhancing access to products for patients in the US

This groundbreaking e-clinic aims to help cardiologists and caregivers manage heart failure patients effectively from the comfort of their homes

This product will be manufactured at Lupin’s Pithampur facility in India

The US FDA has determined that the inspection classification of the facility is Voluntary Action Indicated

This product will be manufactured at Lupin’s Pithampur facility in India

Through this agreement, Lupin will introduce two new formulations

The inspection was carried out from September 25, 2024 to October 4, 2024, and concluded with five observations

According to the agreement, Lupin’s subsidiary in Philippines, Multicare Pharmaceuticals, will file for marketing approval

Consolidated total income of the company increased by 20.43% at Rs 5,226.78 crore for Q3FY24

This product will be manufactured at Lupin’s Nagpur facility in India

Rivaroxaban Tablets USP, 2.5 mg had estimated annual sales of $446 million in the U.S.

Lupin is one of the first ANDA applicants and is eligible for 180 days of shared generic exclusivity

Doxycycline Capsules had estimated annual sales of $215 million in the U.S.

Rocuronium Bromide Injection had estimated annual sales of $54 million in the U.S.

Total consolidated income of the company increased by 12.52% at Rs 5715.02 crore for Q2FY25

Valbenazine Capsules, 40 mg and 80 mg had estimated annual sales of $1,621 million in the US

RLD PENNSAID had estimated annual sales of $509 million in the U.S.

The product marks the first approval from Lupin’s new injectable facility in Nagpur

Lupin is the exclusive first-to-file for this product and is eligible for 180-day exclusivity

The EIR was issued with an inspection classification of Voluntary Action Indicated post the inspection of the facility from September 16 to September 27, 2024

The agreement is for commercialization of the company’s biosimilar Certolizumab Pegol

This product would be manufactured at Lupin’s Nagpur facility in India

Total consolidated income of the company increased by 22.08% at Rs 5,078.96 crore for Q2FY24

Sodium Sulfate, Potassium Sulfate and Magnesium Sulfate Oral Solution (RLD Suprep Bowel Prep Kit) had estimated annual sales of $202 million in the U.S.

Doxycycline Capsules, 40 mg is indicated for the treatment of only inflammatory lesions of rosacea in adult patients

As per the US Food and Drug Administration, the company is recalling the lot for being ‘Subpotent’

Total consolidated income of the company increased by 3.46% to Rs 4,340.18 crore for Q3FY23

Bosentan Tablets for Oral Suspension had estimated annual sales of $11 million in the U.S.

The product will be manufactured at Lupin’s Pithampur facility in India

The product will be manufactured at Lupin’s facility in Goa

NaMuscla, which has been designated orphan drug status, received EU marketing authorization in December 2018

Varenicline Tablets, 0.5 mg and 1 mg is the generic equivalent of Chantix Tablets, 0.5 mg and 1 mg, of PF Prism C.V

Earlier, the company had signed Share Subscription & Shareholders agreement with Sunsure Solarpark and Sunsure

Total consolidated income of the company increased by 14.59% at Rs 4,467.35 crore for Q4FY23

Total consolidated income of the company decreased by 0.09% to Rs 4,160.46 crore for Q2FY23

Both Lupin and Amman Pharma are united in their mission to provide innovative, high-quality healthcare solutions to patients in the MENA region

The USFDA has determined that the inspection classification of the facility is Voluntary Action Indicated

The inspection was conducted from March 6, 2023 to March 10, 2023 and concluded with no observations

The new laboratory in Bengaluru is equipped with cutting-edge technologies

The inspection was conducted from April 8 to April 12, 2024 and concluded with no observations

The product will be manufactured at Lupin’s facility in Goa, India

The Board of Directors of the Company, at its meeting held on February 11, 2025, inter alia, considered and unanimously approved the same

Total consolidated income of the increased by 11.38% at Rs 5821.42 crore for Q3FY25

The Board of Directors at its meeting held on September 11, 2023 has approved the same

Bromfenac Ophthalmic Solution, 0.075% is a generic equivalent of BromSite Ophthalmic Solution, 0.075%, of Sun Pharmaceutical Industries

The inspection closed with issuance of a Form-483 with two observations

The inspection closed without any observation

The company holds the exclusive first-to-file status for this product and will have 180-day generic drug exclusivity

This product will be manufactured at Lupin’s Pithampur facility in India

This product will be manufactured at Lupin’s Somerset facility in the US

The company is committed to enhancing patient access to high-quality, life-enhancing biosimilars

The inspection was conducted from August 7 to August 11, 2023

This product will be manufactured at Lupin’s Pithampur facility in India

The Regional Reference Laboratory in Chennai is equipped with cutting-edge diagnostic technologies and a team of highly qualified clinical experts

This product will be manufactured at Lupin’s Somerset facility in the U.S

This product will be manufactured at Lupin’s Pithampur facility in India

The product will be manufactured at Lupin’s Pithampur facility in India

Ganirelix Acetate Injection had estimated annual sales of $87 million in the U.S.

The product will be manufactured at Lupin’s Pithampur facility in India

This product will be manufactured at Lupin’s Aurangabad facility in India

The total consolidated income of the company increased by 14.71% at Rs 5,724.08 crore for Q4FY25

Pred Forte had estimated annual sales of $198 million in the U.S. (IQVIA MAT August 2024)

Lupin’s transitioning of the portfolio from the simple generic oral solids to complex generics had started with short-acting bronchodilator albuterol

The program includes features designed to encourage healthier lifestyle choices and provides support and care for a healthy heart

Metoprolol Succinate Extended-Release Tablets USP had estimated annual sales of $305 million in the U.S

This product will be manufactured at Lupin’s Pithampur facility in India

The product will be manufactured at Lupin’s Pithampur facility in India

Loteprednol Etabonate Ophthalmic Suspension, 0.5% is bioequivalent to Lotemax Ophthalmic Suspension, 0.5%, of Bausch & Lomb Inc

This partnership will enable Lupin to expand its footprint in China

The EIR was issued following an inspection of the facility conducted from June 10 to June 13, 2024

With this launch, Lupin introduces an alternative to combat COPD, a condition impacting over 15 million adults in the US and ranked as the fourth leading cause of death in the country

The EIR was issued post the last inspection of the facility conducted from October 17, 2022 to October 29, 2022

The study findings were presented at the India Live 2023 symposium in Chennai

This product would be manufactured at Lupin’s Goa facility in India

The product will be manufactured at Lupin’s Nagpur facility in India

Earlier, the company had received approval from board of directors to enter into a business transfer agreement

This acquisition strengthens Lupin’s commitment to providing superior treatment options for patients navigating the complexities of diabetes

As per the USFDA, the company is recalling the affected lot due to ‘failed dissolution specifications’

Valentas and Arnipin tablets are available in 200 mg, 100 mg, and 50 mg

The product will be manufactured at Lupin’s Pithampur facility in India

The inspection closed with the issuance of a Form-483 with three observations

The inspection closed with the issuance of a Form-483 with four observations

LMS offers pharmaceutical CDMO services and is engaged in the manufacturing and supply of APIs

The company has incorporated wholly-owned subsidiary namely ‘Lupinlife Consumer Healthcare’

Under the terms of this agreement, Takeda has granted Lupin non-exclusive patent licensing rights to commercialize Vonoprazan in India

This product will be manufactured at Lupin’s Nagpur facility in India

This rating reflects Lupin’s leadership in environmental transparency and performance and underscores the strategic and systematic efforts in its sustainability journey

Lupin Diagnostics will equip doctors with accurate diagnosis in the patient journey by leveraging innovative technologies for improved patient care

The inspection closed with the facility receiving an inspection classification of ‘No Action Indicated’ (NAI)

Thiamine Hydrochloride Injection USP had estimated annual sales of $35 million in the U.S.

Rocuronium Bromide Injection had an annual sale of around $53 million in the U.S.

Thiamine Hydrochloride Injection USP had an annual sale of around $36 million in the U.S.

Honeywell Solstice Air has the potential to prevent the release of high global warming potential molecules

Paliperidone Extended-Release Tablets had estimated annual sales of $112 million in the U.S.

The inspection concluded with the issuance of a Form 483 with seventeen observations

The acquisition of these two brands expands Lupin’s portfolio of inhalation products in the U.S. and strengthens the company’s presence in the respiratory therapy area

Lupin Diagnostics currently operates 325+ LupiMitra and 23 laboratories in India

The product will be manufactured at Lupin’s facility in Nagpur, India

Lurasidone Hydrochloride Tablets had estimated annual sales of $4.2 billion in the United States

The company has received EIR from USFDA

The affected lot has been produced at Lupin’s Aurangabad plant

This launch reflects Lupin’s unwavering commitment to addressing the critical needs of asthma management in Germany

The partnership aims to prioritize the diagnosis and treatment of these diseases while working to reducing their long-term prevalence

This product will be manufactured at Lupin’s Pithampur facility in India

This product would be manufactured at Lupin’s Pithampur facility in India

This product will be manufactured at Lupin’s Pithampur facility in India

The product will be manufactured at Lupin’s Pithampur facility in India

To date, Lupin has received no reports of illness that appear to relate to this issue

This product would be manufactured at Lupin’s Nagpur facility in India

This award serves as a motivation to continue Nanomi’s mission to revolutionize healthcare

The product will be manufactured at Lupin’s facility in Pithampur, India

This strategic acquisition for the Indian market marks a significant step forward for Lupin as it continues to expand its presence in India

The company initiated the Class II recall on April 18, 2025

This notable achievement highlights the adherence to rigorous quality control measures, reinforcing LDL’s unwavering dedication to providing top-tier diagnostic services

Rufinamide Oral Suspension had estimated annual sales of $72 million in the U.S

The Board of Directors of the company, at its meeting held on March 22, 2024, has approved the same

Lupin Vilfuro-G is the only FDC that uniquely combines Vilanterol, Fluticasone Furoate and Glycopyrronium Bromide, for the long-term management and treatment of moderate to severe COPD

This product will be manufactured at Lupin’s Pithampur facility in India

The product will be manufactured at Lupin’s Pithampur facility in India

This product will be manufactured at Lupin’s Pithampur facility in India

Tolvaptan Tablets are bioequivalent to Jynarque Tablets, 15 mg, 30 mg, 45 mg, 60 mg, and 90 mg, of Otsuka Pharmaceutical Company

Formoterol Fumarate Inhalation Solution (RLD Perforomist) had estimated annual sales of $282 million in the U.S.

LYFE is India’s only evidence-based holistic heart care programme that significantly reduces the risk of a heart attack

This product will be manufactured at Lupin’s Pithampur facility in India

This product would be manufactured at the drug firm’s Nagpur facility and will be supplied to low-and middle-income countries

This collaboration aims to accelerate the application and adoption of DTx in Cardiology in India

Both these products will be manufactured at Lupin’s Injectable facility at Nagpur, India

This guide is based on the American College of Cardiology’s ‘Home-Based Care Workbook’

The inspection of the facility closed with issuance of a Form 483 with eight observations

The cost of acquisition of brands is euro 26 million

Under the terms of the Agreement, I’rom will conduct clinical trials along with Lupin, register, distribute and market biosimilar Denosumab in Japan on an exclusive basis

Pirfenidone Tablets (RLD Esbriet) had estimated annual sales of $218 million in the U.S.

This product will be manufactured at Lupin’s Goa facility in India

Lupin’s new laboratory at Vijayawada is equipped with state-of-the-art diagnostic technology and staffed by a team of highly qualified clinical experts

Desvenlafaxine Extended-Release Tablets, 25 mg is a generic equivalent of Pristiq Extended-Release Tablets, 25 mg of PF PRISM C.V.

Lutio has the potential to offer significant cost savings when available to UK patients

The product will be manufactured at Lupin’s Pithampur facility in India

Prucalopride Tablets, 1 mg, and 2 mg had estimated annual sales of $184 million in the U.S.

The companies have entered into agreement for commercialization of Lupin’s biosimilar ranibizumab across Latin America excluding Mexico and Argentina

The affected lot is manufactured at Lupin’s Goa-based manufacturing facility

The inspection was conducted from March 20, 2023 to March 24, 2023

Valbenazine Capsules had estimated annual sales of $1,235 million in the U.S.

The inspection closed with no observations

Tiotropium Bromide Inhalation Powder (RLD Spiriva) had estimated annual sales of $42 million in Canada

The subsidiary is for undertaking contract development and manufacturing activities

This comes after the satisfactory evaluation of the corrective actions taken by the company in response to the Warning Letter issued by the USFDA

This move reinforces the company’s commitment to making healthcare solutions accessible to all patients

JAI, a visionary initiative by Lupin, equips patients with the knowledge and skills to manage their condition effectively

The inspection closed with three observations each on the API and Finished Product side

Dasatinib Tablets (RLD Sprycel) had estimated annual sales of $1569 million in the U.S. (IQVIA MAT June 2022)

This product will be manufactured at Lupin’s Pithampur facility in India

Formoterol Fumarate Inhalation Solution (RLD Perforomist) had estimated annual sales of $268 million in the U.S.

Sildenafil for Oral Suspension, 10 mg/mL, is a generic equivalent of Revatio for Oral Suspension, 10 mg/mL of Viatris Specialty LLC

The USFDA had inspected the Lupin Tarapur site from March 22, 2022 to April 4, 2022

The product will be manufactured at Lupin’s facility in Nagpur, India

The USFDA has determined that the inspection classification of the facility is Voluntary Action Indicated

This extended-release variant not only ensures consistent alleviation of symptoms but also enhances patient adherence and overall quality of life

Cetuximab has received approval from the DCGI for its effectiveness in treating head and neck cancer

The Huminsulin range of products is indicated for the treatment of type 1 and type 2 diabetes mellitus to improve blood sugar control in both adults and children

This product would be manufactured at Lupin’s Nagpur facility in India

This product will be manufactured at Lupin’s Nagpur facility in India

The inspection closed with issuance of a Form-483 with ten observations

This product will be manufactured at Lupin’s Nagpur facility in India

The inspection closed with issuance of a Form-483 with five observations